Full history for every metric is available with a Kvantra account

Stock profile
Neurocrine Biosciences, Inc. logo

Neurocrine Biosciences, Inc. (NBIX)

Country: United States of AmericaSector: HealthcareIndustry: BiotechnologyExchange: NASDAQ
P/E TTM
22.3
History
P/E NTM
15.9
Market cap
15.24B
Currency USD
KvantraRankAbout65
IValue70
IIQuality84
IIIMomentum31
Current price
150.57 USD-3.84%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$m1,0461,1341,4891,8872,3552,8613,7023,987
Operating profit$m619881
Net profit$m40790155250341479703749
EPS reported$4.676.74
Operating cashflow per share$7.8710.49
Capex per share$0.340.26
FCF per share$7.5210.23
Free cash flow$m7491,040
Net debt$m-1,065-346
Book value equity$m3,2533,879
Book value per share$31.7436.87
Number of sharesm102.5105.2
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx30.3722.34
P/B LTMx4.343.93
P/S LTMx4.934.12
P/FCF LTMx18.8514.66
EV/EBITDA LTMx20.7215.74
EV/Sales LTMx4.834.02
Earnings Yield LTM%3.29%4.48%
FCF Yield%5.31%6.82%
Quality
ROE%14.71%19.74%
ROIC%10.80%14.30%
Operating margin%21.64%23.81%
Gross margin%98.18%97.81%
FCF/Sales%26.17%28.09%
Growth and momentum
EPS Growth YoY%+41.95%+61.24%
Sales Growth YoY%+21.45%+37.98%
Net Income Growth YoY%+40.23%+64.14%
FCF Growth%+34.37%+75.30%
Operating Profit Growth%+8.52%+60.16%
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%0.00%0.00%
FCF/Debtx1.802.65
Net Debt/EBITDAx-0.45-0.26
EBIT/Net interestx-275.38
Net debt/market cap%-7.55%-2.27%
Net debt/Equityx-0.33-0.09
Gross debt/equityx0.130.10

ETFs that hold Neurocrine Biosciences

FundTickerPosition#Weight
First Trust NYSE Arca Biotechnology Index FundFBT43.84%
iShares Morningstar Small-Cap Growth ETFISCG50.58%
Nomura Small and Mid Cap ETFSMDC61.73%
Horizon Small/Mid Cap Core Equity ETFSMOX100.91%
Lazard US Systematic Small Cap Equity ETFSYZ80.67%
First Trust SMID Capital Strength ETFFSCS91.12%

Funds with Neurocrine Biosciences among their ten largest holdings, largest fund first.

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price150.57 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.

Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Neurocrine Biosciences, Inc. (NBIX)

NBIX · NASDAQ · Healthcare
150.57 USD-3.84%
Sign up to track this stock
Benchmarks
KvantraRank65
Market cap15.24B
P/E NTM15.9
P/E TTM22.3
KvantraRank?65 / 100
Value
70
Quality
84
Momentum
31
Financialsin USD
20242025TTM2026E
ETFs that hold Neurocrine Biosciences
FundTickerPosition#Weight
First Trust NYSE Arca Biotechnology Index FundFBT43.84%
iShares Morningstar Small-Cap Growth ETFISCG50.58%
Nomura Small and Mid Cap ETFSMDC61.73%
Horizon Small/Mid Cap Core Equity ETFSMOX100.91%
Lazard US Systematic Small Cap Equity ETFSYZ80.67%
First Trust SMID Capital Strength ETFFSCS91.12%

Funds with Neurocrine Biosciences among their ten largest holdings, largest fund first.

Analyst target
Consensus
Current150.57 USD
Upside
Price consensus
Last year average price target
Current price150.57 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.

IndustryBiotechnology
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free